EU Agency Issues Positive Opinion on Ritlecitinib EU Agency Issues Positive Opinion on Ritlecitinib

In June, ritlecitinib was approved in the United States and Japan for the treatment of severe alopecia areata in adults and adolescents 12 years and older.MDedge News
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Dermatology News Source Type: news